Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorthalidone

FDA-approved product (tablet, oral), marketed as Chlorthalidone, Hemiclor, Hygroton and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Chlorthalidone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Congestive heart failure
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorthalidone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorthalidone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)

    NCT02152969 · start 2014-05

    Registered record
    Registry ID
    NCT02152969
    Conditions
    Hypertension
    Interventions
    Telmisartan; Amlodipine; Chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-05
    Completion
    2014-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan; Amlodipine; Chlorthalidone
    PhasePhase 1
    Registry statusCompleted

  • Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium

    NCT02711670 · start 2014-02

    Registered record
    Registry ID
    NCT02711670
    Conditions
    Kidney Stones
    Interventions
    chlorthalidone; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-02
    Completion
    2017-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stones
    Interventionchlorthalidone; Hydrochlorothiazide
    PhaseNot applicable
    Registry statusCompleted

  • Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure

    NCT01973335 · start 2013-11

    Registered record
    Registry ID
    NCT01973335
    Conditions
    Heart Failure
    Interventions
    Combination therapy with acetazolamide and low-dose loop diuretics; High-dose loop diuretics; Upfront therapy with oral spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-11
    Completion
    2017-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionCombination therapy with acetazolamide and low-dose loop diuretics; High-dose loop diuretics; Upfront therapy with oral spironolactone
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone

    NCT01806363 · start 2012-11

    Registered record
    Registry ID
    NCT01806363
    Conditions
    Hypertension
    Interventions
    Telmisartan 80mg; Chlorthalidone 25mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan 80mg; Chlorthalidone 25mg
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

    NCT01456169 · start 2011-10

    Registered record
    Registry ID
    NCT01456169
    Conditions
    Essential Hypertension
    Interventions
    Azilsartan medoxomil/placebo; Azilsartan medoxomil - chlorthalidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10
    Completion
    2013-01
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAzilsartan medoxomil/placebo; Azilsartan medoxomil - chlorthalidone
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension

    NCT01191450 · start 2011-08

    Registered record
    Registry ID
    NCT01191450
    Conditions
    Arterial Hypertension
    Interventions
    Chlorthalidone 25 mg + amiloride hydrochloride 5 mg; Higroton® Laboratório Novartis
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-08
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionChlorthalidone 25 mg + amiloride hydrochloride 5 mg; Higroton® Laboratório Novartis
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

    NCT01368536 · start 2011-05

    Registered record
    Registry ID
    NCT01368536
    Conditions
    Hypertension; Stage 2 Hypertension; Diabetes
    Interventions
    Valturna; Amlodipine; Chlorthalidone; Placebo of Valturna Tablet; Placebo Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2012-02
    Enrolment
    975

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Stage 2 Hypertension; Diabetes
    InterventionValturna; Amlodipine; Chlorthalidone; Placebo of Valturna Tablet +1 more
    PhasePhase 4
    Registry statusTerminated

  • Resistant Arterial Hypertension Cohort Study

    NCT01083017 · start 2011-04

    Registered record
    Registry ID
    NCT01083017
    Conditions
    Hypertension; Essential Hypertension; Resistant Hypertension
    Interventions
    chlorthalidone; motivational intervention for non-compliant individuals; standardized anti-hypertensive treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-04
    Completion
    2017-05
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Essential Hypertension; Resistant Hypertension
    Interventionchlorthalidone; motivational intervention for non-compliant individuals; standardized anti-hypertensive treatment
    PhaseNot recorded
    Registry statusCompleted

  • Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

    NCT01309828 · start 2011-03

    Registered record
    Registry ID
    NCT01309828
    Conditions
    Safety
    Interventions
    Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-10
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety
    InterventionAzilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

    NCT01033071 · start 2010-01

    Registered record
    Registry ID
    NCT01033071
    Conditions
    Essential Hypertension
    Interventions
    Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-11
    Enrolment
    1,071

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAzilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

    NCT00847626 · start 2009-01

    Registered record
    Registry ID
    NCT00847626
    Conditions
    Hypertension
    Interventions
    Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Chlorthalidone; Chlorthalidone; Azilsartan medoxomil; Azilsartan medoxomil; Azilsartan medoxomil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-07
    Enrolment
    1,711

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAzilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone +7 more
    PhasePhase 3
    Registry statusCompleted

  • One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

    NCT00695955 · start 2007-06

    Registered record
    Registry ID
    NCT00695955
    Conditions
    Hypertension
    Interventions
    Azilsartan medoxomil with or without add-on chlorthalidone; Azilsartan medoxomil with or without add-on hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2010-05
    Enrolment
    669

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAzilsartan medoxomil with or without add-on chlorthalidone; Azilsartan medoxomil with or without add-on hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

    NCT00696384 · start 2007-06

    Registered record
    Registry ID
    NCT00696384
    Conditions
    Hypertension
    Interventions
    Azilsartan medoxomil; Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-04
    Enrolment
    418

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAzilsartan medoxomil; Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Canadian Prevention of Renal and Cardiovascular Endpoints Trial

    NCT00231803 · start 2005-04

    Registered record
    Registry ID
    NCT00231803
    Conditions
    Chronic Kidney Disease
    Interventions
    Combined CKD and CVD Prevention; Cardiovascular Disease prevention; Treatment of Chronic Kidney Disease complications; Usual care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-04
    Completion
    2008-06
    Enrolment
    474

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease
    InterventionCombined CKD and CVD Prevention; Cardiovascular Disease prevention; Treatment of Chronic Kidney Disease complications; Usual care
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

    NCT00353652 · start 2005-01

    Registered record
    Registry ID
    NCT00353652
    Conditions
    Hypertension
    Interventions
    Study#1: chlorthalidone (CTD), titrated dose; Study #1: spironolactone (SP), titrated dose; Study# 2 chlorthalidone (CTD), fixed dose; Study# 2 spironolactone (SP), fixed dose; Study# 2 irbsesartan (IR), fixed dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    2013-01
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionStudy#1: chlorthalidone (CTD), titrated dose; Study #1: spironolactone (SP), titrated dose; Study# 2 chlorthalidone (CTD), fixed dose; Study# 2 spironolactone (SP), fixed dose +1 more
    PhasePhase 4
    Registry statusCompleted